SUDEEP PHARMA
|
|
| BOM : 544619     NSE : SUDEEPPHRM     | |
| LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 17,2026 |
|
Price(EOD): ₹ 871.65
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 9,840.93 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUDEEP PHARMA | 19.6% | 34.7% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | 1.4% | -4.5% | 6.5% |
| DIVIS LABORATORIES | 0.1% | -2.5% | -0.1% |
| TORRENT PHARMACEUTICALS | -2.7% | 1.2% | 39.3% |
| CIPLA | -2.3% | -5.3% | -9.8% |
| DR REDDYS LABORATORIES | -0.5% | -4.7% | -5.4% |
| MANKIND PHARMA | -0.3% | -5.3% | -0.9% |
| LUPIN | -0.3% | 0.6% | 12.3% |
| ZYDUS LIFESCIENCES | -4% | 7.1% | 10.2% |
FUNDAMENTAL ANALYSIS OF SUDEEP PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SUDEEP PHARMA
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
52.59
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 187.20 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 11.15
P/B Calculated based on Book Value of Rs 883.34 Cr
[Latest Year - Mar2026 - Consolidated Results ] 14.59
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 674.89 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
92629% 33043% - |
SHARE PRICE MOMENTUM OF SUDEEP PHARMA
SUDEEP PHARMA vs SENSEX
DEBT OF SUDEEP PHARMA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.27 0.17 0.29 0.24 |
0.27 0.21 0.37 0.28 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF SUDEEP PHARMA
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF SUDEEP PHARMA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
5.8% 4.38% 1.48% 1.76% |
57.82% 59.3% 66.49% 69.06% |
| QtrlyTrend |
8 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
SUDEEP PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE IPO | 4.5% | 6.9% | 12.9% |
| BSE COMMODITIES | 2.3% | -0.6% | 10.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | 5.4% | 7.4% | 2.5% |
| NIFTY SMALLCAP 500 | 4.5% | 5.4% | NA |
| NIFTY TOTAL MARKET | 4% | 2.8% | -0.8% |
| NIFTY IPO INDEX | 3.6% | 6.5% | 8.3% |
You may also like the below Video Courses
FAQ about SUDEEP PHARMA
Is SUDEEP PHARMA good for long term investment?
As on Jun 17,2026, the Fundamentals of SUDEEP PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of SUDEEP PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SUDEEP PHARMA UnderValued or OverValued?
As on Jun 17,2026, SUDEEP PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SUDEEP PHARMA ?
As on Jun 17,2026, the Intrinsic Value of SUDEEP PHARMA is Rs. 1.79 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 0.94
Fair Value [Median EV / Sales Model] : Rs. 2.63
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of SUDEEP PHARMA : Rs. 1.79
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.